Business
PDS completes merger with Edge Therapeutics
PDS completes merger with Edge Therapeutics.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 1921T NetScientific PLC 18 March 2019 \n\nNetScientific plc\n(\"NetScientific\" or the \"Company\")\nPDS completes merger with Edge Therapeutics\n \nFurther to its announcement 26 November 2018, NetScientific plc (AIM: NSCI) is pleased to announce that PDS Biotechnology Corporation, a privately-held Portfolio Company which focuses on late clinical-stage cancer immunotherapy company, and Edge Therapeutics, Inc. (Nasdaq: EDGE) have completed their all share merger and that trading of the combined company will operate under the PDS Biotechnology Corporation name and will start trading on Nasdaq today under the ticker PDSB.\nThe full text of the announcement released by PDS Biotechnology Corporation this morning can be found below.\nCommenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said:\n\"We are delighted that the merger has completed, and with the liquidity attributable to NetScientific's holding in PDS Biotechnology Corporation following the listing on Nasdaq.\"\n \n# # #\nFor more information, please contact:\n\n\n\nNetScientific \nFrançois R. Martelet, M.D., CEO\nIan Postlethwaite, CFO \n \n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\nWH Ireland Limited (NOMAD, Financial Adviser and Broker)\nChris Fielding / Jessica Cave\n \n\n\nTel: +44 (0)20 7220 1666\n \n\n\n\n\nConsilium Strategic Communications \nMary-Jane Elliott / Chris Welsh / Laura Thornton\[email protected]\n\n\nTel: +44 (0)20 3709 5700\n \n\n\n\n \nAbout NetScientific\nNetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.\nFor more information, please visit the website at http://www.NetScientific.net\n \nShares of Combined Company to Commence Trading on Nasdaq Capital Market under New Symbol \"PDSB\" on March 18, 2019\n \nPRINCETON, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (\"PDS Biotechnology\"), a clinical-stage immuno-oncology comp...